FemHealth Focus
Daiichi Sankyo and AstraZeneca’s ENHERTU Recommended for EU Approval for HER2 Low and HER2 Ultralow Metastatic Breast Cancer
Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been recommended for approval in th...
March 03, 2025 | News
Alphamab Oncology and CSPC Dose First Patient in Phase III Trial of JSKN003 for HER2-Positive Breast Cancer
Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has...
February 28, 2025 | News
Akeso Enrolls First Patient in Phase I Trial for HER3-Targeting ADC AK138D1 in Australia
Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in...
February 28, 2025 | News
Akeso Begins Phase III Trial of Ivonescimab for First-Line Treatment of Advanced Triple-Negative Breast Cancer
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced the company has successfully enrolled the first patient in its multicenter, ran...
February 24, 2025 | News
Akeso Doses First Patient in Phase III Trial of Ivonescimab for First-Line Treatment of Triple-Negative Breast Cancer
Akeso, Inc. announced the company has successfully enrolled the first patient in its multicenter, randomized, double-blind Phase III clinical trial of...
February 21, 2025 | News
Adalvo and Wyntra Launch First Women’s Health Treatment in the UK, Expanding Access for Endometriosis Care
Adalvo, in collaboration with Wyntra announce a significant milestone with the first launch from Adalvo’s Women's Health portfolio in the UK, re...
February 20, 2025 | News
NERLYNX® Approved in Thailand for Early and Advanced HER2+ Breast Cancer Treatment
NERLYNX® (neratinib) has been approved as a single agent for the treatment of early-stage HER2+ breast cancer, and in combination with capecitab...
February 18, 2025 | News
RemeGen Presents Promising Phase II Trial Results for Disitamab Vedotin and Toripalimab in Muscle-Invasive Bladder Cancer at ASCO GU 2025
RemeGen Co., Ltd. (RemeGen) has announced new efficacy and safety data from the Phase II clinical trial (NCT05297552, Study ID: RC48-C017) evaluating Disit...
February 17, 2025 | News
Alphamab Oncology Doses First Patient in Phase III Study of Anti-HER2 ADC JSKN003 for Platinum-Resistant Ovarian Cancer
Alphamab Oncology announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparat...
February 14, 2025 | News
OnCusp Therapeutics Secures FDA Fast Track Designation for CUSP06 in Platinum-Resistant Ovarian Cancer
OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validat...
February 13, 2025 | News
Alphamab Oncology and CSPC Launch Phase III Trial for Anti-HER2 ADC JSKN003 in Advanced Breast Cancer
Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has rece...
February 07, 2025 | News
Daiichi Sankyo & AstraZeneca’s Datopotamab Deruxtecan Recommended for EU Approval After Cutting Disease Progression Risk by 37%
Recommendation based on TROPION-Breast01 results showing Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan reduced risk of disease prog...
February 03, 2025 | News
Kazia Therapeutics Launches Clinical Trial for Paxalisib-Immunotherapy Combination in Advanced Breast Cancer
Kazia Therapeutics Limited an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of a clinical trial eval...
January 31, 2025 | News
IMPACT Therapeutics’ Senaparib Gains NMPA Approval as First-Line Maintenance Therapy for Advanced Ovarian Cancer
IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthet...
January 17, 2025 | News
Most Read
- Pioneering Precision: Top 15 Clinical and Lab Diagnostic Companies to Watch in 2025
- 2025 Pharma and Medical Device Trends for Manufacturing Leaders
- 25 High-Value Drugs Losing Patent Protection in 2025: What It Means for Healthcare
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Top Management Shakeups of 2024: Redefining Pharma, Biopharma, and Biotech Leadership
- James Park Joins South Korean LOTTE BIOLOGICS as New CEO to Lead Global Expansion
- Australia Takes the Lead: Moderna Opens Southern Hemisphere’s First mRNA Manufacturing Facility in Victoria
- Eli Lilly Announces $3 Billion Expansion in Wisconsin to Boost Global Medicine Production
- Ngee Ann Polytechnic Partners with Merck Singapore to Elevate Biopharmaceutical Education
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Life Sciences CEOs Bet Big on AI and Workforce Growth Despite Economic and Industry Headwinds
News
